CombiGene and Cell and Gene Therapy Catapult sign agreement to develop manufacturing process for novel gene therapy to treat epilepsy
Collaboration between Cell and Gene Therapy Catapult (CGT Catapult) and Swedish gene therapy company CombiGene will take a unique therapy one step closer to helping sufferers of hard to treat epilepsy.London, UK, and Lund, Sweden, 12 January 2018 – CGT Catapult and CombiGene today announced that they will be collaborating on a project to develop manufacturing processes for CombiGenes drug candidate CG01, a novel gene therapy for treatment of epilepsy. The collaboration aims to develop a complete and final manufacturing process which will allow CombiGene to progress to commercial GMP